FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsSV Labs Corporation
SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.
High risk -
DrugsDarmerica, LLC
FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.
High risk -
DrugsRevive Rx LLC dba Revive Rx Pharmacy
FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.
High risk -
DrugsMusclepower Enterprise Ltd. dba MONSTER KING and GE LABS
FDA warned Musclepower Enterprise (MONSTER KING/GE LABS) over unapproved SARM drugs and undeclared trendione in GE Labs Ykarine.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
Drugs3D Imaging Drug Design and Development LLC
FDA warns 3D Imaging of CGMP failures in sterile PET drug manufacturing and outdated drug listings.
High risk -
DrugsCatalent Indiana, LLC
Catalent Indiana's Bloomington plant released sterile vials contaminated with mammalian hair and failed to investigate, FDA says.
High risk -
DrugsSeaway Pharma Inc.
FDA cited Seaway Pharma for manufacturing-quality rule violations in OTC oral liquid drugs, including release and component-testing failures.
High risk -
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsDeVere Manufacturing Inc.
FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.
High risk -
DrugsRhyz Analytical Labs
FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.
High risk -
DrugsPQ Pharmacy, LLC
FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.
High risk -
DrugsTurbare Manufacturing
FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.
High risk -
DrugsVarunKart Group LLC dba Organic Wellnesses
VarunKart Group sells unapproved Ayurvedic and homeopathic drugs with serious disease claims.
High risk -
DrugsDistacart Inc.
FDA says Distacart's website sells unapproved drugs, some claimed for malaria, asthma, depression and eye conditions.
High risk -
DrugsSwift Digital Group LLC dba Swadesii
FDA warned Swadesii that its website sells unapproved drugs with claims to treat serious conditions including measles, cancer and Alzheimer's.
High risk -
DrugsHandelnine Global, LLC dba Navafresh
Navafresh sells unapproved Ayurvedic drugs online, and its Rheumacare Capsules contain about 7,000 times the lead level of concern.
High risk -
DrugsMahita LLC dba PushMyCart
FDA told online seller PushMyCart its website and Facebook posts sell unapproved drugs claiming to treat measles, cancer, diabetes and Parkinson's.
High risk -
DrugsWells Pharma of Houston, LLC
FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.
High risk -
DrugsOwen Biosciences, Inc.
Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.
High risk -
Drugs123Herbals
FDA warned 123Herbals that SILINTAN and other herbal products are unapproved drugs, and SILINTAN contains hidden meloxicam.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsShoplet
FDA warned Shoplet over website sales of unapproved, misbranded triclosan antiseptic lotion soaps.
Medium -
DrugsSave Rite Medical
Save Rite Medical sold triclosan antiseptic lotion soaps online as unapproved, misbranded new drugs.
Medium -
DrugsMedical Mega
FDA: Medical Mega sells unapproved triclosan antiseptic soaps as nonprescription drugs.
Medium -
DrugsSeema International
FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.
High risk -
DrugsSinsin Pharmaceutical Co., Ltd.
FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.
High risk -
DrugsVerdure Sciences, Inc.
FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.
High risk -
DrugsSiddha Flower Essences, LLC., dba Siddha Remedies
FDA cites Siddha Remedies, a maker of children's homeopathic drugs, for untested water and botanicals and microbial contamination.
High risk -
DrugsWorld Perfumes Inc.
World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsUriel Pharmacy, Inc.
Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.
High risk -
DrugsRNA Bio/Pharma, Incorporated
FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.
High risk -
DrugsMiers Laboratories, Ltd
FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.
High risk -
DrugsKorea Filler Experts
FDA warned Korea Filler Experts that its website sells unapproved and misbranded injectable botulinum toxin drugs, including Nabota 100UI, to U.S. consumers.
High risk -
DrugsIBSPOT.com Inc.
FDA says IBSPOT.com sold unapproved motion sickness patches containing diphenhydramine and diclofenac that the labels never listed.
High risk -
DrugsTaizhou Kangping Medical Science and Technology Co., Ltd.
FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.
High risk -
DrugsCosmenic
FDA warned Panama-based Cosmenic that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsDermacare dba Filler Outlet
South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.
High risk -
DrugsMaypharm
Maypharm website sells unapproved, misbranded Botulax botulinum toxin to U.S. consumers, FDA says.
High risk -
DrugsEstaderma
FDA warned South Korea's Estaderma that its website sells unapproved, misbranded injectable botulinum toxin (Liztox) to U.S. consumers.
High risk -
DrugsKorean Aesthetic dba Korean Fillers
FDA warned Korean Fillers that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsCelestaPro
FDA told CelestaPro its website sells unapproved, misbranded injectable botulinum toxin drugs, including "Nabota 200 Unit", to U.S. consumers.
High risk -
DrugsAceCosm
AceCosm’s website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.
High risk -
DrugsDermax Co., Ltd
FDA warned China's Dermax Co., Ltd. over its website selling unapproved, misbranded injectable botulinum toxin to U.S. consumers.
High risk -
DrugsGlow Nest Beauty
FDA warned Glow Nest Beauty that its website sells unapproved, misbranded injectable botulinum toxin Rentox 200U.
High risk -
DrugsAesthetic Essentials Limited
Hong Kong company Aesthetic Essentials Limited sells not-FDA-approved, mislabeled injectable botulinum toxin drugs online to U.S. consumers.
High risk -
DrugsElle Pharm
FDA warned Elle Pharm that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsCOSMO KOREA
FDA told South Korea's COSMO KOREA that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsGlam Derma
FDA warns Glam Derma over website selling unapproved, misbranded injectable botulinum toxin products.
High risk